Repligen (RGEN) Akcie Kurz
Repligen Kurz
Tržby rostly o 23,2 % ročně za posledních 19 let na 738,26 Mil. USD. Zisk na akcii klesal o 1,8 % ročně za posledních 18 let. čistá marže společnosti Repligen je nyní 6,6 %, dolů z 19,1 % před několika lety. Medián cílové ceny analytiků je 152,50 USD, tedy pod aktuální cenu o 10,9 %. Z 28 analytiků jich 24 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Repligen
Obchodní model Repligen a analýza akcií
Nejčastější otázky týkající se akcie Repligen
Repligen Corp's business model is centered around being a leading provider of products and services for the bioprocessing industry. The company focuses on developing and supplying innovative solutions that enhance the production of biologic drugs. Repligen offers a range of products including bioreactors, filtration systems, chromatography resins, and pre-packed columns. By offering these high-quality and reliable solutions, Repligen aims to support biopharmaceutical companies in improving their manufacturing processes, increasing productivity, and ensuring the quality of their products. Repligen Corp is dedicated to driving advancements in the bioprocessing industry by delivering exceptional products and services to its customers.
Repligen Corp is primarily active in the biotechnology and life sciences industries.
Some of the main competitors of Repligen Corp in the market include Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, and GE Healthcare.
Repligen Corp is a prominent bioprocessing company with a rich history. Founded in 1981, Repligen initially focused on the development of diagnostic products and later expanded its scope to include bioprocessing technologies. Over the years, the company has made significant contributions to the life sciences industry, offering innovative solutions for biomanufacturing needs. Today, Repligen is recognized for its high-quality products and services, serving customers globally. With a commitment to advancing bioprocessing efficiency and productivity, Repligen continues to drive innovation in the field, supporting the development and manufacturing of biologics.
Repligen Corp has achieved several significant milestones. The company successfully completed the acquisition of Spectrum Laboratories in 2012, expanding its product portfolio and enhancing its market presence. In 2014, Repligen received FDA approval for its flagship bioprocessing product, Protein A, which revolutionized the purification of monoclonal antibodies. The company continued its growth by acquiring the business unit of Novavax Inc. in 2015, strengthening its position in the bioprocessing market. Repligen Corp also reached a partnership agreement with Navigo Proteins GmbH in 2019, allowing the development of new affinity ligands. These achievements demonstrate Repligen Corp's dedication to innovation and market leadership.
Repligen Corp is primarily present in several countries and regions. These include the United States, Europe, and Asia.
Repligen Corp is a leading bioprocessing company committed to enhancing biologic drug manufacturing processes. The company's corporate philosophy revolves around key values such as innovation, quality, and collaboration. Repligen Corp strives to provide cutting-edge solutions to improve productivity, efficiency, and consistency in bioproduction through its advanced technologies and expertise. With a focus on customer satisfaction and a passion for advancing bioprocessing technologies, Repligen Corp aims to empower customers and contribute to making biologic medicines more accessible for patients worldwide.
Analytici aktuálně stanovují průměrnou cílovou cenu 152,00 USD pro akcii Repligen (medián: 152,50 USD), tedy -11,2 % vůči poslední ceně. Konsensus vychází z 28 hodnocení analytiků.
28 analytiků aktuálně hodnotí akcii Repligen: 24 doporučuje koupit, 4 držet a 0 prodat. Pro rok 2026 analytici očekávají u Repligen tržby 827,16 Mil. USD a zisk na akcii 2,04 USD.
Při aktuálním kurzu se akcie Repligen obchoduje za 152,74 EUR (171,12 USD).
Akcie Repligen (RGEN) je kótována na 5 burzách, mimo jiné: NASDAQ (RGEN), SIX (Zürich) (RGN.SW), Frankfurt (RGN.F), München (RGN.MU), Düsseldorf (RGN.DU).
Repligen Corp is a leading biotech company specializing in the research, development, and manufacturing of products for bioproduction and cell therapy. The company was founded in 1981 and is headquartered in Waltham, Massachusetts. Repligen Corp's business model is based on four different divisions: bioproduction, chromatography, short-term culture media, and cell therapy. These divisions offer a wide range of products for the research and development community as well as the biopharmaceutical industry. The bioproduction division of Repligen Corp offers a variety of products for the production of recombinant proteins, antibodies, and other therapeutics. These include HGGE and Protein-A affinity resins, the TangenX® membrane separation portfolio, and the XCell™ ATF system for perfusion. The chromatography division of Repligen Corp offers a wide range of products for the purification of proteins and other biologics. These include protein-A affinity resins, reversed-phase resins, HIC and ion exchange resins, and more. The short-term culture media division of Repligen Corp specializes in the development of media for cell cultivation. These include the OptiCHO™, OptiPEAK TiterMAX®, and CellBoost™ portfolios. The cell therapy division of Repligen Corp offers strictly regulated products for clinical applications in cell therapy. These include Syntheglas™ peptides and SAVI™ cell therapy products for the treatment of inflammatory diseases in the gastrointestinal tract. Repligen Corp also offers services and support for its products, including technical consulting and support as well as product training. The company works closely with its customers to ensure that its products meet the specific requirements of the research and biopharmaceutical industry. Overall, Repligen Corp has a strong business model based on the development of innovative products for bioproduction and cell therapy. The company is committed to advancing the development of its products and actively participating in the expansion of the bioproduction industry. Answer: Repligen Corp is a biotech company specializing in the research, development, and manufacturing of products for bioproduction and cell therapy. They offer a range of products for protein production, protein purification, cell cultivation, and cell therapy. The company provides services, support, and product training and aims to contribute to the growth of the bioproduction industry.
Tržby očekávané za Repligen činí 827,16 Mil. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Repligen činí 115,15 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Repligen je aktuálně 83,99. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Repligen.
Poměr ceny k tržbám (P/S) Repligen je aktuálně 11,69. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Repligen.
Score kvality pro Repligen je 4/10.
ISIN Repligen je US7599161095. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Repligen je 870980. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Repligen je RGEN. Symbol tickeru se používá k obchodování akcií Repligen na burze.
Repligen akcie
Repligen Peer Group
Repligen Ticker
Repligen FIGI
Všechny fundamentální údaje o Repligen v podrobné analýze
Naše analýzy akcií společnosti Repligen zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Repligen. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: